Tag: BPCIA
Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biologic patent protection in the U.S. delays biosimilar entry for 12 years after FDA approval, blocking competition and keeping drug prices high. Learn how the BPCIA, patent thickets, and high development costs create a system that benefits manufacturers - not patients.
